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Summary
Background In September, 2016, South Africa adopted a policy of providing antiretroviral treatment to everyone 
infected with HIV irrespective of their CD4 cell count. Studies of universal treatment and expanded prevention of HIV 
differ widely in their projections of effects and the associated costs, so we did this analysis to attempt to find a 
consensus. 
Methods We used data on HIV from the Joint UN Programme on HIV and AIDS (UNAIDS) from 1988 to 2013 and 
from data from WHO on tuberculosis from 1980 to to 2013 to fit a dynamical model to time trends in HIV prevalence, 
antiretroviral therapy (ART) coverage, and tuberculosis notification rates in South Africa. We then used the model to 
estimate current trends and project future patterns in HIV prevalence and incidence, AIDS-related mortality, and 
tuberculosis notification rates, and we used data from the South African National AIDS Council to assess current 
and future costs under different combinations of treatment and prevention approaches. We considered two treatment 
strategies: the Constant Effort strategy, in which people infected with HIV continue to start treatment at the rate in 
2016, and the Expanded Treatment and Prevention (ETP) strategy, in which testing rates are increased, treatment is 
started immediately after HIV is detected, and prevention programmes are expanded.
Findings Our estimates show that HIV incidence among adults aged 15 years or older fell from 2·3% per year in 1996 
to 0·65% per year in 2016, AIDS-related mortality decreased from 1·4% per year in 2006 to 0·37% per year in 2016, 
and both continue to fall at a relative rate of 17% per year. Our model shows that maintenance of Constant Effort will 
have a substantial effect on HIV but will not end AIDS, whereas ETP could end AIDS by 2030, with incidence of HIV 
and AIDs-related mortality rates both at less than one event per 1000 adults per year. Under ETP the annual cost of 
health care and prevention will increase from US$2·3 billion in 2016 to $2·9 billion in 2018, then decrease to 
$1·7 billion in 2030 and $0·9 billion in 2050. Over the next 35 years, the expansion of treatment will avert an additional 
3·8 million new infections, save 1·1 million lives, and save $3·2 billion compared with continuing Constant Effort up 
to 2050. Expansion of prevention, including provision of pre-exposure prophylaxis, condom distribution, and male 
circumcision, could avert a further 150 000 new infections, save 5000 lives, and cost an additional $5·7 billion 
compared with Constant Effort.
Interpretation Our results suggest that South Africa is on track to reduce HIV incidence and AIDS-related mortality 
substantially by 2030, saving both lives and money. Success will depend on high rates of HIV testing, ART delivery 
and adherence, good patient monitoring and support, and data to monitor progress.
Funding None.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
Introduction
One in five people in the world with HIV infection lives 
in South Africa,1 and ending AIDS in the world depends 
on ending AIDS in South Africa. Ending AIDS in South 
Africa represents an opportunity to show what can be 
done and a challenge given the scale of the problem in an 
uncertain health system. The South African Government 
has agreed to provide antiretroviral therapy (ART) to all 
people infected with HIV, irrespective of their CD4 cell 
count, and to expand access to prevention approaches. 
The results of previous studies2,3 show conflicting 
projections of the effects of expanding treatment and 
prevention, thus providing an opportune moment to 
reconsider the likely effects, costs, and cost-effectiveness 
of the new policy.
The first attempt to model the effects of universal 
treatment for everyone infected with HIV in South Africa 
suggested that the rapid expansion of antiretroviral 
therapy (ART) to all those infected with HIV, starting 
in 2010, could have reduced the incidence of HIV and 
AIDS-related mortality in adults to less than 0·1% per year 
by 2020, effectively ending the epidemic. Subsequent 
estimates and projections have been more pessimistic. A 
model developed by the Joint UN Programme on HIV and 
AIDS (UNAIDS) suggests that the incidence of HIV in 
adults in South Africa has stabilised at about 1% per year 
and is not falling.1 The results of another modelling study 
suggest that the expansion of treatment and prevention 
will be effective and cost-effective, but will cost up to 
US$54 billion during the next 10 years.3
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To assess the likely effects and associated costs of 
universal treatment and expanded prevention, we 
developed a dynamical model of HIV and tuberculosis, 
which is driven by the prevalence of HIV, that we used to 
estimate current trends and project future patterns in 
HIV prevalence and incidence, AIDS-related mortality, 
and tuberculosis notification rates and assess current 
and future costs under different combinations of 
treatment and prevention. 
Methods
Study design and data
We fitted a dynamical model4 to data from 1988 to 2013 
on time trends in HIV prevalence and ART coverage 
provided by UNAIDS2 and data on tuberculosis 
notification rates from 1980 to 2013 provided by WHO.5 
We focus on adults, but consideration must also be given 
to the elimination of vertical transmission.6–10
The HIV–tuberculosis model, which has been 
described in detail previously,4 is a standard susceptible–
infected model with four stages of infection to reflect the 
Weibull survival distribution of adults who are not on 
ART11 and is not age-structured. Transmission falls as 
prevalence rises to represent heterogeneity in the risk of 
infection.4 We allowed for increased coverage of voluntary 
male circumcision, pre-exposure prophylaxis (PrEP), and 
condom distribution.
We assumed that tuberculosis in HIV-negative people is 
decreasing at a fixed rate and that the increase in 
tuberculosis among HIV-positive people is driven by the 
prevalence of HIV and coverage of ART. The tuberculosis 
model has two variable parameters: the tuberculosis 
notification rate before the HIV epidemic started and the 
rate of increase with HIV disease progression. We used 
notification rates rather than incidence because estimation 
of the case-detection rate is particularly difficult.12 Provided 
the case-detection rate does not change substantially with 
time, the overall conclusions will not be affected.
Cost estimation
To investigate costs of Contant Effort and ETP, we used 
the cost estimates for the treatment and prevention of 
HIV and tuberculosis,13 assuming a discount rate of 
3% per year. Testing includes the cost of the delivery of 
the test and associated counselling; PrEP includes the 
cost of delivering the drugs; and condom distribution is 
the cost assuming that a man uses an average of 
100 condoms each year. For ART we included the cost of 
drugs, delivery, and support.13 For tuberculosis, the cost 
per patient treated is the total number of notified cases 
divided by the total cost of the tuberculosis programme 
in 2014.5,14 The cost to society of a death from AIDS is 
discussed in the appendix (p 3). 
Assumptions
With our model, we considered two strategies of HIV 
treatment and prevention (table 1), with the associated 
costs shown in table 2. Under the Constant Effort 
strategy, we scaled up testing so that by 2015 people are 
on average being tested once every second year. Under 
Constant Effort, all people who test positive for HIV in 
clinical stage 4, 50% of those in clinical stage 3, 25% of 
those in clinical stage 2, but none of those in clinical 
stage 1 would be started on ART. We multiplied each 
proportion by the overall rate at which people are tested 
and varied this to fit the data. Under the Expanded 
Treatment and Prevention (ETP) strategy, which was 
adopted by the South African Government in September, 
2016, we scaled up testing rates so that by 2020 people 
are being tested on average once per year and everyone 
who tests positive for HIV is started on ART, irrespective 
of their clinical stage or CD4 cell count. Under Constant 
Research in context
Evidence before this study
We did not do a formal systematic review because there are only 
three other models that have been used in this regard. Models 
with varying degrees of complexity have been used to explore the 
possibility of ending AIDS and have been instrumental in 
changing international health policy from starting treatment late 
to starting treatment early. Although broad agreement exists on 
the current state of the HIV epidemic in sub-Saharan Africa the 
models differ in their future projections. 
Added value of this study
Our study attempts to reach a consensus on the future of the 
HIV epidemic in sub-Saharan Africa. In our dynamical model to 
study the effects of treatment and prevention on HIV and 
tuberculosis in South Africa, we paid particular attention to the 
effects of prevention in the context of an ambitious, but 
realistic, roll-out of antiretroviral therapy (ART). Our results 
suggest that ending AIDS in South Africa is both feasible and 
cost-effective and that the added value of prevention depends 
crucially on the effectiveness of the roll-out of ART.
Implications of the available evidence
By considering the cost and effects of treatment under the new 
policy of starting everyone HIV-positive on ART, as well as the 
cost and effects of voluntary medical male circumcision, 
pre-exposure prophylaxis, and condom promotion, our study 
provides guidance for South Africa and other countries with 
generalised HIV epidemics on how best to reach the Joint UN 
Programme on HIV and AIDS (UNAIDS) target of Ending AIDS 
by 2030 and how best to invest their resources. What is most 
urgently needed, in South Africa and elsewhere, is 
strengthening of patient monitoring and routine surveillance 
to asses, in real time, the effects, effectiveness, and 
cost-effectiveness of the control of HIV and tuberculosis.
See Online for appendix
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Effort, we assumed that 92% of people on ART have viral 
suppression on the basis of results from a study in South 
Africa15 and that ART reduces infectiousness by 98·4% 
(appendix p 1). Under ETP, we assumed that 96·5% of 
people on ART had viral suppression on the basis of a 
study in Botswana and that ART reduces infectiousness 
by 99·2% (appendix p 1).16 For people who do not have 
viral suppression, we assumed that ART would reduce 
transmission by 88% (appendix p 1).
Starting in September, 2016, everyone in South Africa 
who tests positive for HIV is eligible for ART, but we 
assumed that full coverage will only be reached in 2025. 
We assumed that voluntary medical male circumcision, 
PrEP, and condom distribution would be rolled out 
from the current to the target coverage during the same 
period. Incidence risk ratios are available in the 
appendix (p 2).17
Role of the funding source
There was no funding source for this study. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Figure 1 shows the fit of the model to the prevalence of 
HIV and ART and tuberculosis notification rates under 
Constant Effort. The HIV transmission parameter, 
which determines the initial rate of increase, was 0·706 
per year; the heterogeneity parameter, which determines 
the peak prevalence,4 was 0·242. In South Africa, unlike 
some countries in eastern and southern Africa,4 there 
was little evidence of a reduction in transmission 
arising from changes in behaviour or prevention 
interventions. The rate of testing increased logistically 
to an asymptote of 0·5 per year, reaching half its 
asymptotic value in 2011. We let the tuberculosis 
notification rate in HIV-negative people fall by 1% per 
year and let the incidence double immediately after 
infection with HIV.18 The best-fit parameters suggest 
that tuberculosis incidence increases by a factor of 2·51 
from one clinical stage to the next or by 49% for each 
decline of 100 CD4 cells per µL, assuming an initial 
CD4 cell count of 1000 per µL.
The fit of the model to HIV prevalence and ART coverage 
is good (figure 1A), whereas the fit to tuberculosis 
notification rates is less good (figure 1B). The roll-out of 
ART has had a substantial effect on both HIV and 
tuberculosis. In 2016, an estimated 58% of all people 
living with HIV were on ART and of these people an 
estimated 92% had viral loads of less than 
400 copies per µL.15 Although the prevalence of HIV has 
remained constant since about 2006 (figure 1A) this 
consistency is largely because the increasing numbers of 
people who are alive on ART balances the reduction in 
the number of new infections. In most countries in 
southern Africa, the tuberculosis model gives good fits 
to trends in tuberculosis notification rates,4 and the 
underlying trend data for the prevalence of HIV based 
on the annual antenatal clinic surveys19 are reliable. 
Tuberculosis notification rates rose rapidly as the 
prevalence of HIV increased after 1990 and have been 
decreasing since ART was rolled out after 2005, although 
tuberculosis notification rates in South Africa might 
warrant more careful examination.
Figure 2 shows the model fit and projections under 
ETP; from September, 2016, everyone who is infected 
with HIV is eligible for treatment. The projected 
incidence of HIV, incidence of ART (ie, the proportion 
of people with HIV infection who start ART each year), 
HIV mortality, and reduction in transmission due to 
each prevention intervention are shown in the appendix 
(p 2).
The incidence of HIV fell from 2·3% per year in 1996 
to 0·65% in 2016 (72% reduction), AIDS-related mortality 
fell from 1·4% per year in 2006 to 0·37% per year in 2016 
(74% reduction), and both continue to fall at a relative 
Constant Effort strategy Expanded Treatment 
and Prevention strategy
Clinical stage 1 0·00 1·00
Clinical stage 2 0·25 1·00
Clinical stage 3 0·50 1·00
Clinical stage 4 1·00 1·00
Viral suppression 0·92 0·965
The proportions of people who test positive for HIV who will start ART are 
shown for each strategy by clinical stage of infection. Viral suppression shows 
the proportion of people on ART who have viral suppression under the different 
strategies. The Constant Effort strategy corresponds to the treatment guidelines 
in South Africa up to September, 2016, whereas the Expanded Treatment and 
Prevention strategy corresponds to the guidelines implemented as of 
September, 2016. ART=antiretroviral therapy.
Table 1: Proportions of people who test positive for HIV and will start 
ART or have viral suppression on ART under different strategies
Estimated cost 
of treatment 
(US$)
Recommended treatment and prevention 
approach or associated outcome
Estimated cost 
of recommended 
treatment or 
outcome (US$)
People not on ART
Clinical stage 1 25 HIV testing (per test) 32
Clinical stage 2 51 ART (per person per year) 274
Clinical stage 3 63 Voluntary male circumcision (per circumcision ) 101
Clinical stage 4 108 PrEP (per person per year) 84
People on ART
Clinical stage 1 48 Condom distribution (per person per year) 5·7
Clinical stage 2 54 Tuberculosis treatment (per patient treated) 780
Clinical stage 3 106 Deaths of young adults (per person) 1100
Clinical stage 4 132 ·· ··
Estimated costs are in 2016 US$.13 We assume a discount rate of 3% per year. ART=antiretroviral therapy. 
PrEP=pre-exposure prophylaxis. 
Table 2: Costs of health care per person per year used to inform the model
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rate of 17% per year. ETP will accelerate the already 
substantial effect of treatment on the epidemic. By 2025, 
we estimate that almost all people infected with HIV will 
be receiving treatment, and by 2030 both incidence and 
mortality will be less than 0·1% per year (ie, less than 
one new case and one death per 1000 adults per year; 
appendix, p 2). The increased coverage of ART will bring 
down the tuberculosis notification rate (figure 2B). The 
number of people on ART will remain high, falling 
slowly as people on ART die of natural causes (figure 2A), 
and the rate at which new people start ART will be very 
low after 2020 (appendix p 2). The UNAIDS estimates of 
incidence, which are based on the same data for HIV 
prevalence and ART coverage as used in this study, differ 
from ours, suggesting that incidence remained fairly 
constant from 2005 to 2015 (appendix p 3). The 
cumulative reduction in the rate of transmission 
resulting from the roll-out of voluntary male 
circumcision, PrEP, and condom distribution is shown 
in the appendix (p 2).
Projected programme costs are shown in the appendix 
(p 4). The cost of voluntary male circumcision peaks as 
the backlog of uncircumcised men is made up; after that 
men only need to be circumcised at the rate at which 
boys reach adulthood. The costs of PrEP and condoms 
both peak in 2020 but then decline as prevalence falls 
and the number of women needing PrEP and men 
needing condoms fall with it.
With random testing, 1/P people, where P is the 
prevalence of HIV, would need to be tested to find one 
person infected with HIV. As the prevalence falls, testing 
will become more focused and we let N(t)—the number 
of people who are tested at time t for each person found 
to be infected with HIV—be as follows:
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Figure 2: Estimates and projections under Expanded Treatment and Prevention strategy
(A) Prevalence of HIV and ART; denominator is adults aged 15 years or older; outer lines show 95% CIs. (B) Tuberculosis notification rates; denominator is the whole 
population. Data points show the points used to inform the model and the smooth lines show projections.  ART=antiretroviral therapy.
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(A) Prevalence of HIV and ART; denominator is adults aged 15 years or older; outer lines show 95% CIs. (B) Tuberculosis notification rates; denominator is the whole 
population. Data points show the points used to inform the model and the smooth lines show projections. ART=antiretroviral therapy.
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where T(t) is the proportion of people who start 
treatment and P(t) is the prevalence of HIV at time t; this 
model assumes that it would never be necessary to test 
more than 20 people to find one infected person. 
Assessing the cost to society of letting young, working 
age adults die is difficult. In our model, we set the cost to 
the health services of each AIDS-related death to 15% of 
the gross domestic product (GDP) per person per year 
(appendix p 4). The model shows that in 2006, the cost of 
deaths due to AIDS peaked at about $684 million 
per year; after that the cost falls as ART is rolled out and 
the major cost becomes that of ART provision, which is 
currently about $1·1 billion per year.
Figure 3 shows the total costs of managing HIV and 
treating tuberculosis. The cost of providing health care to 
people not on ART is substantial but only until 2020. The 
cost of providing other health care to people on ART is 
typically about 15% of the cost of ART. The cost of PrEP is 
relatively small compared with the main health-care 
costs; the cost of voluntary male circumcision is 
substantial but only for about 5–10 years as the backlog of 
uncircumcised men is made up. The cost of condom 
distribution is negligible and the cost of tuberculosis 
treatment is never more than about 5% of the total cost 
once the epidemic of HIV has become established.
The total annual cost peaks at about $2·9 billion 
in 2018 but then falls rapidly to $1·7 billion in 2030 and 
$861 million in 2050. The annual cost is never more than 
0·8% of GDP. In 2013, total spending on HIV and 
tuberculosis in South Africa was ZAR22 billion13 or 
$2·3 billion, taking the average exchange rate for the 
year of ZAR9·5 to $1. Our estimate for 2013 is $1·7 billion. 
If we assume that overhead costs and costs associated 
with HIV in infants and children are about 25% of the 
total costs, our estimates and the reported total 
expenditure (ZAR22 billion or $2 billion using the 2011 
exchange rate)13 are in good agreement.
Figure 4 shows the number of new infections and 
AIDS-related deaths that would be expected with various 
combinations of interventions between 2016 and 2050. 
Under Constant Effort, which uses the pre-2016 
guidelines and the current rate of scale-up of treatment, 
we would expect 5·00 million new HIV infections and 
1·66 million AIDS-related deaths at a cost of 
$55·5 billion between 2016 and 2050. Implementing the 
new treatment guidelines whereby all HIV-positive 
people receive ART will avert 3·76 million new infections, 
save 1·14 million lives, and save $3·2 billion. The 
addition of voluntary male circumcision will avert a 
further 66 000 new infections and save 2300 lives, but 
will cost an additional $676 000 at $10 000 per infection 
averted and $294 000 per life saved. The addition of PrEP 
will avert a further 53 000 new infections and save 
2000 lives but will cost an additional $4·9 billion, 
at $92 000 per infection averted and $2·5 million per life 
saved. The addition of condom distribution will avert a 
further 33 000 new infections and save 12 000 lives, but 
will cost an additional $131 million at $4000 per infection 
averted and $11 000 per life saved.
Discussion
South Africa has more people living with HIV and on 
ART than any other country. Our study shows that the 
successful roll-out of ART has been associated with a 
72% reduction in the incidence of HIV among adults 
from 1996 to 2016 and a 74% reduction in AIDS-related 
mortality from 2006 to 2016.Our model shows that if 
South Africa continues to scale up testing, provides 
treatment to everyone infected with HIV, invests in 
treatment support, and provides access to prevention for 
people at high risk of infection, HIV incidence and 
AIDS-related mortality will both be less than one event 
per 1000 people by 2030 and South Africa will effectively 
end AIDS (appendix p 2).
The increasing coverage of ART will substantially 
reduce the incidence of tuberculosis, but it should be 
noted that although ART reduces the risk of developing 
tuberculosis by 60%, people on ART are still at greater 
risk of developing tuberculosis than are those who are not 
infected with HIV.18 The sooner people with HIV infection 
start ART, the greater will be the effect on tuberculosis, 
but control of tuberculosis will ultimately depend on 
controlling tuberculosis in HIV-negative people.
According to our model, the cost of counselling and 
testing is never more than about 5% of the total cost, and 
since testing is the foundation of treatment, it will be 
essential to invest sufficient resources in it. The cost of 
tuberculosis treatment is less than 10% of the total and 
falling; given that tuberculosis is the major cause of 
AIDS-related illness and deaths, efforts should be made 
to optimise tuberculosis treatment. The total cost of the 
management of HIV and tuberculosis in South Africa is 
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currently about $2·1 billion (0·6% of GDP) and this will 
rise to a peak of $2·9 billion in 2018 (0·8% of GDP). As 
treatment is scaled up and prevention made available to 
people at high risk of infection, the cost will fall to 
$1·7 billion in 2030 and $0·9 billion in 2050 as those 
living with HIV on ART die from natural causes.
We estimate that between 2016 and 2050, the expansion 
of treatment from the Constant Effort scenario to the ETP 
scenario will avert 3·8 million infections, save 1·1 million 
lives and save $3·2 billion. If treatment targets are met, 
the strategy will eliminate almost all AIDS-related deaths. 
Our study suggests that, during this period, the expansion 
of prevention efforts will avert a further 150 000 new 
infections and save 5000 lives at a cost of $5·7 billion. 
However, equity demands that people at high risk of 
infection have access to the best possible methods of 
protection, and if public health programmes focus 
complementary prevention efforts on individuals at high-
risk of infection, these approaches will be cost-effective. 
For example, among people in groups with an incidence 
of HIV greater than 10% per year, and if PrEP reduces the 
risk of infection by about 50% and costs $100 per person 
per year, PrEP will cost $2000 per infection averted 
compared with the $93 000 per infection averted if PrEP 
were distributed evenly in the whole population. If 
voluntary male circumcision reduces the risk of infection 
by 60% and the risk of infection over 10 years is, for 
example, 80%, then the cost will be $250 to avert one 
infection in one man.
Prevention interventions only contribute a small part 
of the overall cost of HIV management and will be cost-
effective if targeted at people at high risk of HIV infection. 
Although the additional effects on HIV of voluntary male 
circumcision will be small in the context of ETP, 
voluntary male circumcision also protects men against 
other sexually transmitted infections20–22 and women 
from acquiring human papillomavirus, which can lead to 
cervical cancer.23–25 
In a previous study, Walensky and colleagues3 reported 
that efforts to rapidly reach the UNAIDS 90–90–90 targets 
in South Africa are a necessary step towards epidemic 
control and are cost-effective. However, their assumptions 
about ART expansion, efficacy, and treatment costs are 
more conservative than ours, leading to different results 
(appendix p 4). During the next 10 years, the Walensky3 
Current Pace strategy predicts about twice as many new 
infections and six times as many deaths as in our 
Constant Effort strategy, whereas their UNAIDS strategy 
predicts about six times as many new infections and 
12 times as many deaths as in our ETP strategy. 
Furthermore, the estimated total cost for the next 10 years 
in the Walensky model3 is about twice that of our model 
(appendix p 5). The main difference between the two 
models is that the Walensky model3 assumes that the 
proportion of people infected with HIV who are on ART 
saturates at 81%. We assumed that once 70% of people 
with HIV infection are on ART, people will continue to be 
tested and started on ART so that the proportion on ART 
will continue to increase; the Walensky model3 assumes 
that, without treatment, about 35% of all transmission 
would occur during the acute phase, but we do not 
include an additional contribution to transmission during 
the acute phase of infection (appendix p 5).
Modelling studies for Mozambique26 and South Africa27 
have predicted different outcomes depending on the 
parameterisation. In these studies, the crucial parameter 
is the proportion of people on ART who do not have viral 
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suppression. The Mozambique study26 assumes that 
under a so-called Accelerated Scale-up scenario, 85% of 
people with a CD4 cell count of less than 350 per µL, or 
about 50% of all those infected with HIV, are on ART and 
that ART reduces the infectivity of patients’ HIV by 80%. 
The South African study27 assumes that 77% (55–94%) of 
those on ART are virally suppressed. If ART coverage is 
low or if many people on ART do not have viral 
suppression, South Africa will not end AIDS.
Our modelling study suggests that with a commitment 
to get as many people as possible onto ART while 
ensuring high levels of adherence and viral load 
suppression, it will be possible to end AIDS in 
South Africa by 2030. The increase in the coverage of 
ART has already had a substantial effect on tuberculosis 
notification rates and further increases will have an even 
greater impact. If the roll-out of ART is successful, the 
additional effects of expanding the various prevention 
methods will have a proportionally small effect on the 
overall epidemic.
Expansion of access to testing and treatment is both 
feasible and cost-effective and will result in substantial 
reductions in transmission, illness, and deaths while 
greatly reducing the burden of HIV on health services.28 
Relative to expanded treatment, prevention will have a 
small additional effect on infections averted or lives 
saved. However, although the overall number of 
infections will be greatly reduced, there might still be 
small but difficult to reach populations at substantial 
risk of infection, including female sex workers, men 
who have sex with men, and intravenous drug users. 
Public health officials will need to remain vigilant by 
making the best possible methods of prevention 
available to susceptible populations. Once overall 
epidemic control has been reached, people with HIV 
infection will still need active case management and 
social support, whereas those not infected with HIV will 
need access to the best possible methods of prevention. 
The end of AIDS does not mean the end of HIV and 
South Africa will have a substantial number of people 
living with HIV infection for the next 50 years or until a 
cure is found, and these people will need continuing 
care and support.
Programme performance matters and ending AIDS 
will require focus and efficient service delivery to ensure 
early diagnosis, sustained treatment and good surveillance 
to monitor progress and identify and correct weaknesses 
and failures. The markers of success will be the proportion 
of all people infected with HIV who are on ART and the 
viraemia in those on ART. The most important weakness 
in the assessment of progress and projection of the future 
of the epidemic remains the absence of good surveillance 
and patient monitoring systems in many of the worst 
affected countries, including South Africa. The main 
limitation of our study (and similar studies) is the scarcity 
of reliable trend data, especially for HIV incidence and 
AIDS-related mortality; if such data were available, they 
would constrain the model predictions to a much greater 
degree. Models are only as good as the data that inform 
them and efforts must be made to collect, assemble, 
synthesise, and analyse much better data on patient 
monitoring and surveillance.
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